Cargando…
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine m...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156127/ https://www.ncbi.nlm.nih.gov/pubmed/37134157 http://dx.doi.org/10.1126/sciadv.adf0108 |
_version_ | 1785036475467825152 |
---|---|
author | Frieling, Jeremy S. Tordesillas, Leticia Bustos, Xiomar E. Ramello, Maria Cecilia Bishop, Ryan T. Cianne, Junior E. Snedal, Sebastian A. Li, Tao Lo, Chen Hao de la Iglesia, Janis Roselli, Emiliano Benzaïd, Ismahène Wang, Xuefeng Kim, Youngchul Lynch, Conor C. Abate-Daga, Daniel |
author_facet | Frieling, Jeremy S. Tordesillas, Leticia Bustos, Xiomar E. Ramello, Maria Cecilia Bishop, Ryan T. Cianne, Junior E. Snedal, Sebastian A. Li, Tao Lo, Chen Hao de la Iglesia, Janis Roselli, Emiliano Benzaïd, Ismahène Wang, Xuefeng Kim, Youngchul Lynch, Conor C. Abate-Daga, Daniel |
author_sort | Frieling, Jeremy S. |
collection | PubMed |
description | Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration–approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR-independent activation of γδ CAR-T cells, increased cytokine secretion, and enhanced antitumor efficacy. These data show that the activity of the endogenous Vγ9Vδ2 T cell receptor is preserved in CAR-T cells, allowing for dual-receptor recognition of tumor cells. Collectively, our findings support the use of γδ CAR-T cell therapy for mCRPC treatment. |
format | Online Article Text |
id | pubmed-10156127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101561272023-05-04 γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer Frieling, Jeremy S. Tordesillas, Leticia Bustos, Xiomar E. Ramello, Maria Cecilia Bishop, Ryan T. Cianne, Junior E. Snedal, Sebastian A. Li, Tao Lo, Chen Hao de la Iglesia, Janis Roselli, Emiliano Benzaïd, Ismahène Wang, Xuefeng Kim, Youngchul Lynch, Conor C. Abate-Daga, Daniel Sci Adv Biomedicine and Life Sciences Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration–approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR-independent activation of γδ CAR-T cells, increased cytokine secretion, and enhanced antitumor efficacy. These data show that the activity of the endogenous Vγ9Vδ2 T cell receptor is preserved in CAR-T cells, allowing for dual-receptor recognition of tumor cells. Collectively, our findings support the use of γδ CAR-T cell therapy for mCRPC treatment. American Association for the Advancement of Science 2023-05-03 /pmc/articles/PMC10156127/ /pubmed/37134157 http://dx.doi.org/10.1126/sciadv.adf0108 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Biomedicine and Life Sciences Frieling, Jeremy S. Tordesillas, Leticia Bustos, Xiomar E. Ramello, Maria Cecilia Bishop, Ryan T. Cianne, Junior E. Snedal, Sebastian A. Li, Tao Lo, Chen Hao de la Iglesia, Janis Roselli, Emiliano Benzaïd, Ismahène Wang, Xuefeng Kim, Youngchul Lynch, Conor C. Abate-Daga, Daniel γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title | γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title_full | γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title_fullStr | γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title_full_unstemmed | γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title_short | γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer |
title_sort | γδ-enriched car-t cell therapy for bone metastatic castrate-resistant prostate cancer |
topic | Biomedicine and Life Sciences |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156127/ https://www.ncbi.nlm.nih.gov/pubmed/37134157 http://dx.doi.org/10.1126/sciadv.adf0108 |
work_keys_str_mv | AT frielingjeremys gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT tordesillasleticia gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT bustosxiomare gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT ramellomariacecilia gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT bishopryant gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT ciannejuniore gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT snedalsebastiana gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT litao gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT lochenhao gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT delaiglesiajanis gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT roselliemiliano gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT benzaidismahene gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT wangxuefeng gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT kimyoungchul gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT lynchconorc gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer AT abatedagadaniel gdenrichedcartcelltherapyforbonemetastaticcastrateresistantprostatecancer |